US 12,234,281 B2
Antibody-based therapy of transthyretin (TTR) amyloidosis and human-derived antibodies therefor
Jan Grimm, Dübendorf (CH); and Aubin Michalon, Baden (CH)
Assigned to Neurimmune Holding AG, Schlieren (CH)
Filed by Neurimmune Holding AG, Schlieren (CH)
Filed on Nov. 22, 2021, as Appl. No. 17/532,292.
Application 17/532,292 is a division of application No. 16/413,335, filed on May 15, 2019, granted, now 11,180,545.
Application 16/413,335 is a division of application No. 15/106,176, granted, now 10,344,080, issued on Jul. 9, 2019, previously published as PCT/EP2014/079094, filed on Dec. 22, 2014.
Claims priority of application No. 13199251 (EP), filed on Dec. 20, 2013.
Prior Publication US 2022/0144928 A1, May 12, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/00 (2006.01); A61K 39/395 (2006.01); C07K 16/18 (2006.01); G01N 33/68 (2006.01)
CPC C07K 16/18 (2013.01) [G01N 33/6896 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/52 (2013.01); C07K 2317/565 (2013.01); C07K 2317/92 (2013.01); G01N 2800/28 (2013.01); G01N 2800/7047 (2013.01)] 13 Claims
OG exemplary drawing
 
1. A recombinant anti-transthyretin (TTR) antibody that binds mutated, misfolded, misassembled, and/or aggregated TTR species and/or fragments thereof and does not recognize physiological TTR species, wherein the antibody comprises a human fragment crystallizable (Fc) region of an IgG1 isotype and comprises complementarity determining regions (CDRs), wherein:
(i) CDR-H1 comprises the amino acid sequence of SEQ ID NO: 104;
(ii) CDR-H2 comprises the amino acid sequence of SEQ ID NO: 105;
(iii) CDR-H3 comprises the amino acid sequence of SEQ ID NO: 106;
(iv) CDR-L1 comprises the amino acid sequence of SEQ ID NO: 107;
(v) CDR-L2 comprises the amino acid sequence of SEQ ID NO: 108; and
(vi) CDR-L3 comprises the amino acid sequence of SEQ ID NO: 109.